Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed.
作者信息
Kasper Philipp, Demir Münevver, Steffen Hans-Michael
机构信息
University of Cologne, Faculty of Medicine, and University Hospital Cologne, Department of Gastroenterology and Hepatology, Cologne, Germany.
Department of Hepatology and Gastroenterology, Campus Virchow Clinic, Charité University Medicine, Berlin, Germany.
出版信息
Clin Mol Hepatol. 2023 Apr;29(2):390-393. doi: 10.3350/cmh.2023.0059. Epub 2023 Mar 20.
Abstract
摘要
相似文献
1
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed.非酒精性脂肪性肝病的筛查策略：需要一种整体方法。
Clin Mol Hepatol. 2023 Apr;29(2):390-393. doi: 10.3350/cmh.2023.0059. Epub 2023 Mar 20.
2
Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).用于诊断非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）的单一非侵入性模型。
J Gastroenterol Hepatol. 2014 Dec;29(12):2006-13. doi: 10.1111/jgh.12665.
3
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.2020 年非酒精性脂肪性肝病/非酒精性脂肪性肝炎临床实践循证指南。
J Gastroenterol. 2021 Nov;56(11):951-963. doi: 10.1007/s00535-021-01796-x. Epub 2021 Sep 17.
4
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.他汀类药物单独使用，或与吡格列酮及其他药物联合使用，用于治疗非酒精性脂肪性肝病/非酒精性脂肪性肝炎及相关心血管风险。专家小组声明。
Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4.
5
Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.非酒精性脂肪性肝病治疗在 2 型糖尿病患者中；新的问题出现了。
Curr Vasc Pharmacol. 2020;18(2):172-181. doi: 10.2174/1570161117666190405164313.
6
Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).预测非酒精性脂肪性肝病（NAFLD）患者非酒精性脂肪性肝炎（NASH）和肝纤维化进展的因素。
Trop Doct. 2018 Apr;48(2):107-112. doi: 10.1177/0049475517742261. Epub 2017 Nov 16.
7
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.前瞻性评估大型美国中年队列中非酒精性脂肪性肝病和脂肪性肝炎的患病率。
J Hepatol. 2021 Aug;75(2):284-291. doi: 10.1016/j.jhep.2021.02.034. Epub 2021 Mar 18.
8
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.一项关于欧洲对非酒精性脂肪性肝病公共卫生应对措施的横断面研究。
J Hepatol. 2020 Jan;72(1):14-24. doi: 10.1016/j.jhep.2019.08.027. Epub 2019 Sep 10.
9
ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.ADAMTSL2 蛋白和可溶性生物标志物特征可识别非酒精性脂肪性肝病成人的非酒精性脂肪性肝炎和纤维化高危人群。
J Hepatol. 2022 Jan;76(1):25-33. doi: 10.1016/j.jhep.2021.09.026. Epub 2021 Oct 1.
10
Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels.联合和序贯无创方法诊断非酒精性脂肪性肝病伴持续正常丙氨酸氨基转移酶水平患者的非酒精性脂肪性肝炎。
BMJ Open Diabetes Res Care. 2020 Mar;8(1). doi: 10.1136/bmjdrc-2020-001174.
引用本文的文献
1
The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review.脂肪肝指数（FLI）在非酒精性脂肪性肝病管理中的作用：一项系统评价
Diagnostics (Basel). 2023 Oct 26;13(21):3316. doi: 10.3390/diagnostics13213316.
2
Prognostic value of coronary artery calcium score for the prediction of atherosclerotic cardiovascular disease in participants with suspected nonalcoholic hepatic steatosis: Results from the multi-ethnic study of atherosclerosis.冠状动脉钙评分对疑似非酒精性脂肪性肝病患者预测动脉粥样硬化性心血管疾病的预后价值：来自动脉粥样硬化多民族研究的结果。
Am Heart J. 2023 Nov;265:104-113. doi: 10.1016/j.ahj.2023.07.008. Epub 2023 Jul 28.
本文引用的文献
1
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990-2019: A DALY-based analysis of the Global Burden of Disease 2019 study.全球原发性肝癌负担及其与潜在病因、社会人口地位和性别差异的关系：基于残疾调整生命年的 2019 年全球疾病负担研究分析。
Clin Mol Hepatol. 2023 Apr;29(2):433-452. doi: 10.3350/cmh.2022.0316. Epub 2023 Jan 4.
2
Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease.儿童和青年非酒精性脂肪性肝病患者的心血管疾病风险
Gut. 2023 Mar;72(3):573-580. doi: 10.1136/gutjnl-2022-328105. Epub 2022 Dec 15.
3
Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: The Dong-gu study.韩国人群中肝纤维化生物标志物与全因和心血管疾病死亡率的关系：东固研究。
PLoS One. 2022 Dec 13;17(12):e0277729. doi: 10.1371/journal.pone.0277729. eCollection 2022.
4
Screening strategy for non-alcoholic fatty liver disease.非酒精性脂肪性肝病的筛查策略。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S103-S122. doi: 10.3350/cmh.2022.0336. Epub 2022 Nov 30.
5
Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population.对平均风险人群中晚期纤维化的纤维化-4指数和非酒精性脂肪性肝病纤维化评分的重新评估。
Front Med (Lausanne). 2022 Nov 3;9:1024836. doi: 10.3389/fmed.2022.1024836. eCollection 2022.
6
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.全球非酒精性脂肪性肝病的患病率和发病率：系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):851-861. doi: 10.1016/S2468-1253(22)00165-0. Epub 2022 Jul 5.
7
Incidence of Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病儿童 2 型糖尿病的发病率。
Clin Gastroenterol Hepatol. 2023 May;21(5):1261-1270. doi: 10.1016/j.cgh.2022.05.028. Epub 2022 Jun 13.
8
COVID-19, childhood obesity, and NAFLD: colliding pandemics.2019冠状病毒病、儿童肥胖与非酒精性脂肪性肝病：相互交织的大流行
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):499-501. doi: 10.1016/S2468-1253(22)00100-5.
9
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者的血脂异常管理。
Curr Atheroscler Rep. 2022 Jul;24(7):533-546. doi: 10.1007/s11883-022-01028-4. Epub 2022 May 4.
10
Uncontrolled hypertension: A neglected risk in patients with NAFLD.未控制的高血压：非酒精性脂肪性肝病患者中被忽视的风险。
J Intern Med. 2022 Jul;292(1):162-164. doi: 10.1111/joim.13476. Epub 2022 Mar 6.
Zotero 插件